High TILs percentage (>50%) was an independent positive prognostic factor.<h4>Conclusions</h4>In patients with HER2-positive breast cancer treated with adjuvant trastuzumab, the percentage of TILs, stroma type, and PD-L1 expression are prognostically relevant. The gene discussed is ERBB2; the disease is breast cancer.